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Patient specific therapy is emerging as an important possibility for many cancer
patients. However, to identify such therapies it is essential to determine the
genomic and transcriptional alterations present in one tumor relative to control
samples. This presents a challenge since use of a single sample precludes many
standard statistical analysis techniques. We reasoned that one means of
addressing this issue is by comparing transcriptional changes in one tumor with
those observed in a large cohort of patients analyzed by The Cancer Genome Atlas
(TCGA). To test this directly, we devised a bioinformatics pipeline to identify
differentially expressed genes in tumors resected from patients suffering from the
most common malignant adult brain tumor, glioblastoma (GBM). We performed
RNA sequencing on tumors from individual GBM patients and filtered the results
through the TCGA database in order to identify possible gene networks that are
overrepresented in GBM samples relative to controls. Importantly, we demonstrate
that hypergeometric-based analysis of gene pairs identifies gene networks that
validate experimentally. These studies identify a putative workflow for uncovering
differentially expressed patient specific genes and gene networks for GBM and
other cancers.
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Introduction
Glioblastoma multiforme (GBM) is the most common malignant adult brain
tumor, comprising 15.6% of all central nervous system tumors [1]. The median
two-year survival is 13.7%, and disease remission following standard therapy
occurs within 6.9 months. [1, 2] Treatment includes surgical resection followed by
radiation and temozolomide (TMZ) administration. However, TMZ resistance is
nearly universal, suggesting that we need to understand the genetic landscape of
GBM tumors more extensively in order to uncover more effective therapies [3].
Recent developments in oncogenomics point to a highly heterogeneous
genomic landscape in GBM [4, 5]. Importantly, this heterogeneity necessitates
genome and transcriptome analyses of each tumor individually in the hopes of
discovering patient specific therapies [6]. However, discovering patient–specific
transcriptional alterations is difficult given the low patient sample size (n51).
This is especially true when using RNA sequencing given the discordance of
different RNA-Seq alignment and analysis algorithms when sample size is small
[7].
One possibility to increase the available sample size is to utilize transcriptome
data in publicly available databases as a reference. For instance, The Cancer
Genome Atlas (TCGA) has performed gene expression microarray analysis in over
400 GBM patients examining them using two different platforms (Agilent and
Affymetrix). Thus, it is possible to use these data as a reference set, to compare the
RNA sequencing results from a single tumor sample and identify differentially
expressed genes and gene networks. Utilizing a novel bioinformatics pipeline we
were able to perform a patient-specific analysis of the GBM transcriptome based
on the overlap between our RNA-Seq data and the TCGA GBM data. This
approach allowed us to identify and filter out potential artifacts due to low sample
size.
In this report we identified a patient specific list of differentially expressed genes
(DEGs), which can be used as input for multiple types of analyses including gene
co-expression networking. Genes that co-express across multiple samples are often
implicated in similar functions [8] and many disease-associated genes have been
discovered through co-expression network analysis [9]. Most methods used in
previous studies are based on the calculation of correlation coefficients (usually
Pearson) of gene pairs as an indication of co-expression. Furthermore, either
weighted [10] or unweighted [11] processes involving the proposed connections
between genes are used to determine the significance thresholds for assigning a
connection between any two nodes (i.e., genes) in the resulting network. Our
studies suggest that utilizing correlation and hypergeometric tests identifies
experimentally validated gene connections, which can potentially assist in
discovering patient specific therapies.
Patient Specific GBM Gene Networks
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Materials and Methods
RNAseq quality control and genome mapping
We performed whole transcriptome sequencing on two GBM tumors (GBM17
and GBM31) and two control samples from epileptic patients using the Illumina
HiSeq sequencing platform. Preliminary screening was performed in FastQC
(FASTQC 2012) and BLAST [12] to assess the sequence read quality and to filter
for potential adapter contamination. Low quality reads were trimmed and
adapters were removed in downstream analysis. Remaining reads from each
sample were mapped to the human genome using TopHat Version 2.0.4 [13],
[14].
After read trimming, samples GBM17, GBM31, Control16, and Control34 had
87.18%, 78.56%, 86.79%, and 92.31%, reads mapped, respectively. For each
sample, we also assessed the distribution of genes that mapped to the human
genome in order to gauge the quality of the experiment. GBM17, GBM31, and
Control 34 yielded approximately 15,000 genes with nearly 100% transcript
coverage in the reference human genome. Control16 had only 8,085 mapped
genes. Only the common 8,085 genes were used in the 4 differential expression
analyses that followed.
RNAseq Differential Expression Evaluation
Four differential expression analysis tools, rather than one single tool, were
applied to the data and the results from all four tools were compared. This yielded
results that are relatively robust to both varying tool approaches to sequencing
depth normalization and statistical tests employed, as well as to inherent
variability in the RNA-Seq data. The four methods used were: baySeq 1.10.0 [15],
DESeq 1.8.3 [16], edgeR 2.6.12 [17], and Cuffdiff 2 [13].
TCGA Microarray Expression Data
Two expression datasets were collected from The Cancer Genome Atlas (TCGA)
in 07/02/2014 (https://tcga-data.nci.nih.gov/tcga/). The first dataset contained
tumor specific expression data from 433 glioblastoma patients (P1-P433) and the
second dataset contained brain tissue expression data from 10 epileptic patients.
All samples were analyzed with both the AgilentG4502A Microarray Platform and
the Affymetrix HG-U133 Microarray Platform. The Level 3 (processed) data for
these samples were downloaded and further analyzed. The data processing and
quality control were performed by The Broad Institute’s TCGA workgroup. The
AgilentG4502A Level 3 data consisted of the lowess normalized log2 expression
values [18]. The Affymetrix HG-U133 Data were RMA normalized and hence are
on a log2 scale [19].
Differentially expressed (DE) genes between glioblastoma patients and epileptic
controls were identified by using the limma package in R [20] (moderated t-
statistic and also the Benjamini and Hochberg’s method to control for FDR). Out
of the 17,814 genes detected by the AgilentG4502A Platform, 6,889 genes were
Patient Specific GBM Gene Networks
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found to be differentially expressed (FDR adjusted p-value,0.05). Out of the
12,042 genes detected by the Affymetrix HG U133 Platform, 7,503 genes were
differentially expressed (FDR adjusted p-value,0.05). Filtering for genes that had
a minimum fold change was not performed at this step, as it would only depict the
gene expression tendency according to the average of all the patients and may
conceal any gene expression patterns that characterize particular subgroups of
patients. Minimum fold change filtering was performed at a later stage of the
analysis. Patient specific gene expression fold change was calculated for each
patient relative to the average gene expression in the TCGA tissue specific
controls.
Hypergeometric Test
A hypergeometric-based test was used to assess the significance of co-expression
across samples between two genes of a gene pair. The rationale behind using the
hypergeometric test was that if 2 genes had any biological and/or functional
association, they would be found co-expressed in a higher number of samples
than expected by chance. We tested under the null hypothesis that the property of
a gene to be DE in one sample is independent of the property of another gene to
be DE in the same sample. The p-value was derived from the hypergeometric
function below where f: total number of patients, d: number of patients for which
Gene1 is DE, g: number of patients for which Gene2 is DE, n: number of patients













Our pipeline and the scripts for calculating the Pearson Correlation Coefficient
and the Hypergeometric test can be found in (S4 Fig., S1 File).
Creating Networks
Networks from the selected gene pairs were created using the open source
Cytoscape 3.1.0 as described in [21]. Further, the STRING9.1 Protein-Protein
Interaction Platform [22] was employed to verify the functional relevance of the
discovered networks.
Results
Identifying genes differentially expressed in GBM via RNA
sequencing and TCGA enrichment
We performed RNA sequencing on 2 GBM tumors (GBM17 and GBM31) and 2
epilepsy control tissues (Control16 and Control34) using the Illumina HiSeq
Patient Specific GBM Gene Networks
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platform. Focusing on patient specific transcriptionally expressed genes, we
compared the transcriptome of each tumor individually with the two controls. In
order to ameliorate the increased uncertainty of the different algorithms due to
low sample size [7], we used four, rather than one, differential expression tools
(baySeq, Cuffdiff, EdgeR and DESeq), as described in the Materials and Methods
Section. As expected, the four algorithms yielded mostly non-overlapping lists of
differentially expressed genes. We defined a given gene as ‘differentially expressed
(DE)’ if at least three of the four algorithms called the gene as differentially
expressed. By performing this type of analysis, we identified 1,081 DE genes for
GBM17 and 967 genes for GBM31, respectively (Fig. 1, S1 Fig.).
In order to assess whether these results represent the phenotype of interest
(GBM) or individual sample variability, we compared our RNA sequencing results
to results from a greater number of samples, namely, the TCGA microarray
dataset. Previous studies have shown that RNA-Seq results can be compared to
those derived from microarrays [23, 24, 25]. We created a TCGA DE gene list by
comparing TCGA patients and TCGA controls. In order to avoid any platform
specific biases, we selected only TCGA patients (n5433) and controls (n510) that
were analyzed with both microarray platforms (Agilent and Affymetrix). When we
examined these data, we found that 5,200 genes were found by both platforms to
be DE and concordant, i.e, not upregulated in one platform and downregulated in
another platform. Of these 5,200 DE genes, we found that 585 are DE in GBM17
and 514 are DE in GBM31 (S1 Fig.). In S2 Fig. we can see that when using the
consensus of at least 3 algorithms, the number of common DE genes between our
RNAseq data and the TCGA data remains relatively the same. On the other hand,
when only one algorithm was taken into account, the number of overlapping
genes (between RNAseq and TCGA) was greatly dependent on the fold change
threshold selection. Therefore, we opted for the 1.2 fold change threshold, in an
attempt to obtain a high and significantly relevant number of genes.
Identifying Gene Pairs and Networks Using Hypergeometric Test
Analysis
As acquired drug resistance is one of the main reasons for the ineffectiveness of
current glioblastoma treatment, the identification and simultaneous inhibition of
multiple therapeutic targets is essential for identifying effective combination
therapies. However, the large genetic variation among glioblastoma tumors
necessitates a more patient-specific approach when identifying potential
therapeutic targets. For this, we tried to create gene networks based only on genes
that were DE in that specific RNA-Seq sample. After determining the DE genes for
each sample, and ‘filtering’ or selecting those that are also DE in the TCGA data,
we searched for any significant co-expression among these patient-specific DE
genes in the TCGA data. Our hypothesis was that if there were any functional
association between gene pairs, then this association could be observed based
upon their co-expression in the TCGA population. We utilized two methods to
identify co-expression. First, the Pearson Correlation Coefficient (PCC) was used
Patient Specific GBM Gene Networks
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Fig. 1. Pipeline for identifying patient-specific gene association in GBM. Our first step in our pipeline is to identify Differentially Expressed (DE) genes
that are represented in 3 out of 4 algorithms. Next, we filter this DE gene list for those genes that overlapped with DE genes in the TCGA GBM Database. We
then calculate the Correlation Coefficient and a hypergeometric p-value for every gene pair. Finally, by selecting the gene pairs with the highest correlation
values we create a patient specific gene correlation network, which can be experimentally verified. As a starting point for our experiments, we can use the
sub-networks in which, already verified connections exist in the literature.
doi:10.1371/journal.pone.0115842.g001
Patient Specific GBM Gene Networks
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to determine if the expression level of one gene could be indicative of the
expression level of the second gene. Next, a hypergeometric test was used to
calculate the probability of a pair of genes being both DE in a specific number of
patients by chance. Gene pairs with a low p-value indicate the tendency of these
genes to be DE together in a higher number of patient samples than we would
expect by chance. For every gene pair, we plotted both its PCC and its
hypergeometric probability in the TCGA population (S1 Fig.). Our results
indicate that pairs of genes that are DE in a larger proportion of patient samples
also have more highly correlated expression values across the total TCGA GBM
cohort. Finally, as outliers heavily influence the PCC, we calculated the Spearman
Correlation Coefficient for every gene pair as well. As shown in S3 Fig. we found
that gene pairs with high PCC also have a very high Spearman Correlation
Coefficient, indicating that the PCCs we calculated were generally not the
byproduct of outliers.
As our aim was to define patient-specific and glioblastoma-relevant gene
networks, we used the most statistically significant gene pairs in each RNA-Seq
sample in order to reconstruct the networks. Our most significant gene pairs (S1
Table) consisted of the ones that had a PCC above 0.7 and were in the lowest 40%
of the range of the hypergeometric log10 scale ([246.15, 227.69] for GBM17 and
[244.72, 226.83] for GBM31). These gene pairs were selected for each patient
sample separately and were imported to Cytoscape [26] where the network was
created. In order to verify the functional relevance of these networks, we employed
the STRING9.1 Protein-Protein Interaction Platform [22]. STRING 9.1 can take
into account a variety of sources in order to reconstruct networks out of a given
gene list. For our study, we only chose the conservative options of searching in
Databases, Experiments and Text-mining. To ensure the accuracy of the text-
mining algorithm, we manually verified the text mining output. As shown in
Fig. 2, there is overlap between the networks created from our pipeline and gene
associations indicated by STRING 9.1. To examine whether the hypergeometric
test yielded greater experimentally verified interactions, we kept the PCC filter
(.0.70) constant but varied the hypergeometric test p-values. As before, we
compared our gene networks with curated interaction data via STRING 9.1. As
shown in Fig. 3 and S2 Table, fewer experimental data validated the gene network
connections created by these gene pairs when we only used a PCC filter. Thus, our
studies suggest that a hypergeometric distribution test can potentially enrich more
experimentally verified gene pairs.
Identifying Epigenetic-Signaling Pathway Interactions Based on
Hypergeometric Test Analysis
Several studies suggest that epigenetic and signaling pathways control GBM
progression [27]. We therefore reasoned that the gene networks robustly
uncovered by the bioinformatics pipeline described above would potentially
include the interactions of DE genes involved in signaling or epigenetic pathways.
To test this, we created a discrete gene list consisting of 464 genes (through KEGG
Patient Specific GBM Gene Networks
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Fig. 2. Correlation networks created by using the top gene pairs for each patient. The number of connections we identified were compared to those
previously described in the literature (red). Yellow indicates connections, which were identified in protein-protein interaction databases.
doi:10.1371/journal.pone.0115842.g002
Fig. 3. Gene Networks created by Pairs with high PCC (greater than 0.7) and high hypergeometric p-value yield less experimentally verified
interactions. The number of connections identified was calculated for gene pairs with high PCC and high hypergeometric p-values. These connections
were then compared to those identified in the literature. Note that few connections were found to be experimentally validated.
doi:10.1371/journal.pone.0115842.g003
Patient Specific GBM Gene Networks
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Pathways) (S3 Table) that encoded for either epigenetic modulators, or genes
implicated in the Notch, Shh and Wnt Pathways. Out of the 464 Epigenetic/
Pathway (E/P) related genes, 418 genes were differentially expressed in the TCGA
GBM data from the Agilent Microarray Platform. In order to find the non-
random co-expression of E/P genes together with genes that were differentially
expressed on each patient, we employed our pipeline. As shown in Fig. 4, the
more statistically significant gene pairs have a higher expression correlation in the
whole population of 433 GBM patients. These studies yielded potential
interactions of signaling pathways or epigenetic regulators with GBM patient
specific DE genes.
Discussion
Combination therapies that effectively disrupt multiple pathways are likely to
reduce GBM recurrence. However, identifying these therapies is contingent upon
uncovering patient-specific genomic and transcriptomic alterations. One major
issue is how to generate robust analytical results from gene expression data when
sample size is low. To circumvent this problem, we elected to employ multiple
different RNA-Seq algorithms and compare the results common to most
algorithms with results based on the transcriptional profile of over 400 GBM
tumors analyzed by TCGA. With this approach, we identified genes that not only
were differentially expressed in our patient specific sample but also were
differentially expressed in a significant number of TCGA patient samples. These
true positive genes were subsequently used to create gene co-expression networks
to identify any potential functional similarity. By using a hypergeometric test in
addition to the PCC, we identified experimentally validated gene-gene
interactions.
One gene network that has been experimentally verified in multiple biological
contexts is the highly conserved MCM (Mini-Chromosome Maintenance)
network containing the DNA replication licensing factors MCM2, MCM3, and
MCM7. We identified this network as overexpressed in GBM sample 31. With the
hypergeometric test, we detected a high probability of the MCM subunits to be
overexpressed in the same patient samples in the TCGA dataset and were able to
distinguish them from other gene pairs that only showed a high correlation
coefficient (but little co-occurrence within patients). Importantly, the MCM
pathway has been implicated in multiple cancers including GBM [28, 29]. Thus,
our pipeline can be utilized to identify DE gene-gene interactions and networks in
GBM that have a higher likelihood of validation relative to interactions and
networks identified by correlation alone.
The stringency of our filtering of the DE genes from any given patient, however,
is likely to also yield false negatives. For instance, we chose to only explore DE
genes that were detected in at least 3 out of 4 RNA-Seq algorithms, which may
have excluded some true positives. It may be informative to use other statistical
methods in addition to the hypergeometric test to determine whether there are
Patient Specific GBM Gene Networks
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alternative approaches that would also yield results that are enriched for
experimentally verified gene networks. In addition any proposed pipeline will
involve subjective choices of thresholds and criteria for significance. We have
made reasonable choices, but it is possible that moving to nonparametric and
permutation-based results to establish a more systematic approach to threshold
selection could lead to pipeline improvements. Nonetheless, our studies identify a
robust method for identifying patient-specific gene networks, which can inform
the design of effective combination therapies.
We implemented this method to identify potential targets for combination
therapies involving epigenetic pathways and the Notch, SHH, and WNT
pathways. Our recent studies and those from other laboratories suggest that
epigenetic pathways contain attractive new therapeutic targets in GBM [30, 31].
Similarly, the Notch, SHH, and WNT pathways are implicated in GBM cell
growth and have been linked to epigenetic pathways [27]. Thus, we reasoned that
identifying interaction nodes between either signaling pathways or epigenetic
modulators and DE genes could lead to potential synergy in reducing tumor
growth. We identified possible nodes of interaction among epigenetic and
signaling pathways using our pipeline. Interestingly, we identified possible
interaction of the DNA methyltransferase DNMT1 with the MCM proteins
(Fig. 4). However, these interactions have not been experimentally verified
according to STRING 9.1. Nonetheless, they may exist in some GBM patients as
DNMT1 has been shown to be a potential GBM therapeutic target whose
inhibition leads to an increase of several tumor suppressor genes [32, 33, 34].
Future studies will experimentally verify whether drug combinations that target
these gene-gene networks are useful clinically for treating GBM.
Supporting Information
S1 Fig. Overlap of DE genes calculated by 4 RNAseq Algorithms (EdgeR,
Bayseq, Cufflinks, DEseq). We analyzed genes that were shown to be DE by at
least 3 out of the 4 algorithms (* symbol). We then filtered for genes that were
shown to be DE by both Microarray Platforms in the TCGA GBM cohort and also
were shown to have a |fold change|.1.2. The Pearson Correlation Coefficient and
the p-value of the hypergeometric test were then plotted for every gene pair.
doi:10.1371/journal.pone.0115842.s001 (TIF)
S2 Fig. Fold Change dependent overlap of DE genes calculated by 4 RNAseq
Algorithms and the TCGA Database. The fold change threshold did not change
the number of overlapped genes between the RNAseq and the TCGA analysis,
when the consensus of 3+ RNAseq algorithms was used.
Fig. 4. Correlation networks identified that intersect epigenetic pathways/signaling pathways with patient specific DE genes. Connections were
calculated for gene-gene pairs emanating from epigenetic pathways or genes in the Notch, SHH, or WNT pathways and genes that were Differentially
Expressed in each patient.
doi:10.1371/journal.pone.0115842.g004
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doi:10.1371/journal.pone.0115842.s002 (TIFF)
S3 Fig. Comparison between two Correlation Coefficients. The Pearson and the
Spearman Correlation Coefficients were calculated for every gene pair. In both
patients gene pairs with high Pearson Correlation Coefficient show also high
values for the Spearman Correlation Coefficient.
doi:10.1371/journal.pone.0115842.s003 (TIF)
S4 Fig. Pipeline for calculating the Hypergeometric Distribution and the
Pearson Correlation Coefficient for every gene pair.
doi:10.1371/journal.pone.0115842.s004 (TIFF)
S1 Table. Gene pairs consisting of the ones that had a PCC above 0.7 and were
in the lowest 40% of the range of the hypergeometric log10 scale.
doi:10.1371/journal.pone.0115842.s005 (XLSX)
S2 Table. Gene pairs with a PCC above 0.7 and the highest hypergeometric
log10 scale values.
doi:10.1371/journal.pone.0115842.s006 (XLSX)
S3 Table. Gene list containing 464 genes are either epigenetic modulators, or
genes implicated in the Notch, Shh and Wnt Pathways (though KEGG
Pathways).
doi:10.1371/journal.pone.0115842.s007 (XLSX)
S1 File. Perl scripts used in the pipeline.
doi:10.1371/journal.pone.0115842.s008 (TXT)
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